Headlines

J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports

Published by Global Banking & Finance Review

Posted on May 2, 2025

1 min read

· Last updated: January 24, 2026

Add as preferred source on Google
K+S revenue report highlights Q2 revenue miss and sales volume drop - Global Banking & Finance Review
Image illustrating K+S's Q2 financial report, showing a decline in revenue and sales volume due to logistical challenges. Relevant to banking and finance news.
Global Banking & Finance Awards 2026 — Call for Entries

(Reuters) -HistoSonics, a medical technology company backed by Johnson & Johnson, is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday,

HistoSonics Considers $2.5 Billion Sale Amid Interest

(Reuters) -HistoSonics, a medical technology company backed by Johnson & Johnson, is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing people familiar with the matter.

The company is seeking a valuation of more than $2.5 billion, the report said.

(Reporting by Bipasha Dey in Bengaluru; Editing by Sonia Cheema)

Key Takeaways

  • HistoSonics is exploring a potential sale.
  • The company seeks a valuation over $2.5 billion.
  • Johnson & Johnson backs HistoSonics.
  • Multiple takeover approaches have been received.
  • The report was published by the Financial Times.

Frequently Asked Questions

What is the main topic?
The main topic is HistoSonics exploring a potential sale with a valuation of over $2.5 billion.
Who backs HistoSonics?
HistoSonics is backed by Johnson & Johnson.
What valuation is HistoSonics seeking?
HistoSonics is seeking a valuation of more than $2.5 billion.

Related Articles

More from Headlines

Explore more articles in the Headlines category